Abeona Therapeutics Inc.
ABEO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $4 | $1 | $3 |
| % Growth | -100% | 147.5% | -52.9% | – |
| Cost of Goods Sold | $3 | $2 | $0 | $0 |
| Gross Profit | -$3 | $2 | $1 | $3 |
| % Margin | – | 54.1% | 68.2% | 100% |
| R&D Expenses | $34 | $31 | $29 | $39 |
| G&A Expenses | $30 | $19 | $17 | $22 |
| SG&A Expenses | $30 | $19 | $17 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3 | -$1 | $6 | $32 |
| Operating Expenses | $61 | $49 | $52 | $93 |
| Operating Income | -$64 | -$47 | -$51 | -$90 |
| % Margin | – | -1,346.7% | -3,600.8% | -2,994.5% |
| Other Income/Exp. Net | $0 | -$7 | $11 | $5 |
| Pre-Tax Income | -$64 | -$54 | -$40 | -$85 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$64 | -$54 | -$40 | -$85 |
| % Margin | – | -1,548.2% | -2,807.4% | -2,831.2% |
| EPS | -1.55 | -2.53 | -5.53 | -21.5 |
| % Growth | 38.7% | 54.2% | 74.3% | – |
| EPS Diluted | -1.55 | -2.53 | -5.53 | -21.5 |
| Weighted Avg Shares Out | 41 | 21 | 8 | 4 |
| Weighted Avg Shares Out Dil | 41 | 21 | 8 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $2 | $0 | $0 |
| Interest Expense | $4 | $0 | $1 | $4 |
| Depreciation & Amortization | $3 | $3 | $5 | $4 |
| EBITDA | -$57 | -$51 | -$34 | -$77 |
| % Margin | – | -1,444.9% | -2,431.6% | -2,560.5% |